Assembly Biosciences, Inc. Lease, Cost
Assembly Biosciences, Inc. (ASMB) reported Lease, Cost of $1.67 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-03-19
- Assembly Biosciences, Inc. lease, cost for the quarter ending 2021-12-31 was $1.16M, a 47.84% decline year-over-year.
- Assembly Biosciences, Inc. lease, cost for the quarter ending 2021-09-30 was $1.21M, a 27.84% decline year-over-year.
- Assembly Biosciences, Inc. lease, cost for the quarter ending 2021-06-30 was $1.36M, a 18.19% decline year-over-year.
- Assembly Biosciences, Inc. lease, cost for the quarter ending 2021-03-31 was $1.55M, a 1.24% increase year-over-year.
- Assembly Biosciences, Inc. lease, cost for fiscal 2025 was $1.67M, a 22.24% decline from fiscal 2024.
- Assembly Biosciences, Inc. lease, cost for fiscal 2024 was $2.15M, a 56.41% decline from fiscal 2023.
- Assembly Biosciences, Inc. lease, cost for fiscal 2023 was $4.92M, a 0.55% decline from fiscal 2022.
- Assembly Biosciences, Inc. lease, cost for fiscal 2022 was $4.95M, a 6.34% decline from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $1.67M 10-K · filed 2026-03-19 | |||
| 2024-12-31 | $2.15M 10-K · filed 2026-03-19 | |||
| 2023-12-31 | $4.92M 10-K · filed 2025-03-20 | |||
| 2022-12-31 | $4.95M 10-K · filed 2024-03-28 | |||
| 2021-12-31 | $1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $2.37M derived: sum of 2 quarters · filed 2023-03-22 | $3.73M derived: sum of 3 quarters · filed 2023-03-22 | $5.28M 10-K · filed 2023-03-22 |
| 2021-09-30 | $1.21M 10-Q · filed 2021-11-04 | $2.57M derived: sum of 2 quarters · filed 2021-11-04 | $4.13M 10-Q · filed 2021-11-04 | $6.34M derived: sum of 4 quarters · filed 2022-03-11 |
| 2021-06-30 | $1.36M 10-Q · filed 2021-08-05 | $2.92M 10-Q · filed 2021-08-05 | $5.13M derived: sum of 3 quarters · filed 2022-03-11 | $6.81M derived: sum of 4 quarters · filed 2022-03-11 |
| 2021-03-31 | $1.55M 10-Q · filed 2021-05-06 | $3.77M derived: sum of 2 quarters · filed 2022-03-11 | $5.45M derived: sum of 3 quarters · filed 2022-03-11 | $7.11M derived: sum of 4 quarters · filed 2022-03-11 |
| 2020-12-31 | $2.22M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $3.89M derived: sum of 2 quarters · filed 2022-03-11 | $5.56M derived: sum of 3 quarters · filed 2022-03-11 | $7.08M 10-K · filed 2022-03-11 |
| 2020-09-30 | $1.67M 10-Q · filed 2021-11-04 | $3.34M derived: sum of 2 quarters · filed 2021-11-04 | $4.87M 10-Q · filed 2021-11-04 | $6.37M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $1.67M 10-Q · filed 2021-08-05 | $3.20M 10-Q · filed 2021-08-05 | $4.69M derived: sum of 3 quarters · filed 2021-08-05 | $6.22M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $1.53M 10-Q · filed 2021-05-06 | $3.03M derived: sum of 2 quarters · filed 2021-05-06 | $4.55M derived: sum of 3 quarters · filed 2021-05-06 | $6.08M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $1.49M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $3.02M derived: sum of 2 quarters · filed 2021-02-25 | $4.55M derived: sum of 3 quarters · filed 2021-02-25 | $6.26M 10-K · filed 2021-02-25 |
| 2019-09-30 | $1.52M 10-Q · filed 2020-11-05 | $3.05M derived: sum of 2 quarters · filed 2020-11-05 | $4.76M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $1.53M 10-Q · filed 2020-08-05 | $3.24M 10-Q · filed 2020-08-05 | ||
| 2019-03-31 | $1.71M 10-Q · filed 2020-05-08 | |||
| 2018-12-31 | $4.20M 10-K · filed 2021-02-25 | |||
| 2017-12-31 | $2.10M 10-K · filed 2020-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |